Movement Alert｜Abivax S.A. Falls 5.38% in After-Hours Trading, Phase 3 Trial Safety Controversy Continues to Suppress Rebound Momentum

Market Focus06-26 04:05

On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.

On the news front, the ongoing safety controversy surrounding the company's core drug obefazimod continues to weigh on the stock. The Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dosing group, triggering a sharp decline from approximately $130 to around $70 — a drop of nearly 50%. While some investors subsequently argued the cancer cases were more likely age-related, prompting a partial recovery above $100, market consensus on the safety issue remains unresolved. Technical rebound momentum has progressively weakened, with the stock resuming its downtrend over recent sessions.

Within the Biotechnology sector, AbbVie down 0.18%, Revolution Medicines unchanged, Gilead Sciences up 0.5%, Amgen up 0.65%, Ascendis Pharma unchanged.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100699073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100699073","market":"us","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Falls 5.38% in After-Hours Trading, Phase 3 Trial Safety Controversy Continues to Suppress Rebound Momentum","media":"Market Focus","content":"<p><p>On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.</p><p>On the news front, the ongoing safety controversy surrounding the company's core drug obefazimod continues to weigh on the stock. The Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dosing group, triggering a sharp decline from approximately $130 to around $70 — a drop of nearly 50%. While some investors subsequently argued the cancer cases were more likely age-related, prompting a partial recovery above $100, market consensus on the safety issue remains unresolved. Technical rebound momentum has progressively weakened, with the stock resuming its downtrend over recent sessions.</p><p>Within the Biotechnology sector, AbbVie down 0.18%, Revolution Medicines unchanged, Gilead Sciences up 0.5%, Amgen up 0.65%, Ascendis Pharma unchanged.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Falls 5.38% in After-Hours Trading, Phase 3 Trial Safety Controversy Continues to Suppress Rebound Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Falls 5.38% in After-Hours Trading, Phase 3 Trial Safety Controversy Continues to Suppress Rebound Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.</p><p>On the news front, the ongoing safety controversy surrounding the company's core drug obefazimod continues to weigh on the stock. The Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dosing group, triggering a sharp decline from approximately $130 to around $70 — a drop of nearly 50%. While some investors subsequently argued the cancer cases were more likely age-related, prompting a partial recovery above $100, market consensus on the safety issue remains unresolved. Technical rebound momentum has progressively weakened, with the stock resuming its downtrend over recent sessions.</p><p>Within the Biotechnology sector, AbbVie down 0.18%, Revolution Medicines unchanged, Gilead Sciences up 0.5%, Amgen up 0.65%, Ascendis Pharma unchanged.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1100699073","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100699073","pubTimestamp":1782417955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.On the news front, the ongoing safety controversy surrounding the company's core drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"动向提示|Abivax S.A.盘后跌5.38%，3期试验安全性争议继续打压反弹动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On June 26, Abivax S.A. fell 5.38% in after-hours trading, trading at $92.37/share, with turnover of $247,000.On the news front, the ongoing safety controversy surrounding the company's core drug obefazimod continues to weigh on the stock. The Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dosing group, triggering a sharp decline from approximately $130 to around $70 — a drop of nearly 50%. While some investors subsequently argued the cancer cases were more likely age-related, prompting a partial recovery above $100, market consensus on the safety issue remains unresolved. Technical rebound momentum has progressively weakened, with the stock resuming its downtrend over recent sessions.Within the Biotechnology sector, AbbVie down 0.18%, Revolution Medicines unchanged, Gilead Sciences up 0.5%, Amgen up 0.65%, Ascendis Pharma unchanged.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100699073","isCrawlerRequest":true}